Desmopressin in cases of compromised primary hemostasis: Monitoring of platelet function with the PFA-100;Desmopressin bei thrombozytenfunktionsstorung: Nachweis des therapieeffektes mit dem Platelet Function Analyzer PFA-100

Anasthesiologie und Intensivmedizin

Volumn 40, Issue 7-8, 1999, Pages 555-562

  Kretschmer, V ^a   Weippert Kretschmer, M ^b  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b NONE

Author keywords

Blood platelets; Critical care; Desmopressin; Equipment and supplies; von Willebrand's disease

Indexed keywords

ADRENALIN; DESMOPRESSIN; HEMOSTATIC AGENT;

ARTICLE; BLEEDING TIME; BLOOD; BLOOD CLOTTING DISORDER; BLOOD CLOTTING PARAMETERS; DIAGNOSTIC VALUE; DRUG EFFECT; HEMOSTASIS; HUMAN; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; VON WILLEBRAND DISEASE;

EID: 0032869355     PISSN: 01705334     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Beck K-H, Mohr P, Bleckmann U, Schweer H, Kretschmer V: Desmopressin effect on acetylic-acid impaired platelet function. Semin Thromb Hemost 21 (Suppl 2) (1995) 32-39
2. Bennet J S: Disorders of platelet function: Evaluation and treatment. Cleve Clin J Med 58: (1991) 413-417
3. Bergmann F, Drewke E, Budde U: Sensitivity and specifity of the pfa 100® analyser regarding disorders of hemostasis. Ann Hematol 74 (suppl 2) (1997) A 54
4. Budde U, Kussmann J: Hömostasestörungen bei Patienten mit Blutungsanamnese, persönliche Mitteilung 1999
5. Casonato A, Pontara E, Dannhaeuser D, Bertomoro A, Sartori M T, Zerbinat P, Girolami A: Re-evaluation of the therapeutic efficacy of DDAVP in type 2B von Willebrand's disease. Blood Coagulation Fibrinolysis 5 (1994) 959-964
6. Castaman G, Rodeghiero F: Desmopressin and type 2B von Willebrand disease. Hemophilia 2 (1996) 73-77
7. Cattaneo M, Moia M, Valle P D, Castellana P, Mannucci P M: DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor. Blood 74 (1989) 1972-1975
8. De Caterina R, Lanza M, Mane G, Strata G B, Maffei S, Salvatore L: Bleeding time and bleeding: An analysis of the relationship of the bleeding time test with parameters of surgical bleeding. Blood 84 (1994) 3363-3370
9. De Rossi S, Glick M: Bleeding time: An unrealiable predictor of clinical hemostasis. J Oral Maxillofac Surg 54 (1996) 1119-1120
10. Dietrich G, Kretschmer V, Weber D, Haupt W, Langen B, Huss B: Variables influencing the Thrombostat 4000: Recommended standardization. Semin Thrombos Hemost 21 (suppl 2) (1995) 11-19
11. Dietrich G, Kretschmer V: Primary hemostasis in hemodilution 1. Influence of the hematocrit. Infusionsther 17 (1990) 212-213
12. Dietrich G, Kretschmer V: Primary hemostasis in hemodilutin 2. Influence of various infusion solutions. Infusionsther 17 (1990) 214-216
13. Fragneto R Y, Datta S: Epidural analgesia in a preeclamptic parturient after normalization of a prolonged bleeding time with DDAVP. Regional Anesthesia 20 (1995) 448-451
14. Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, Meyer D: Screening for von Willebrand Disease with a new analyzer using high shear stress: A study of 60 cases. Blood 91 (1998) 1325-1331
15. Kratzer M A A, Belluci S, Cean J P: Detection of abnormal platelet function with an in vitro model of primary haemostasis. Haemostasis 15 (1985) 363-370
16. Kratzer M A A, Born G V R: Simulation of primary haemostasis in vitro. Haemostasis 15 (1985) 347-362
17. Kretschmer V, Leicht E, Rothmund M, Zeiler T, Karger R: Perioperative therapy and monitoring of acquired von Willebrand disease (vWD) - Case report. Ann Hematol 78 (suppl. 1) (1999) A60 (Abstract P 102)
18. Kretschmer V, Marsian F, Zeiler T, Weippert-Kretschmer M: ASS sensitivity of the in-vitro-bleeding-test (IVBT) with platelet function analyzer 100 (PFA-100). Ann Hematol 78 (suppl. 1) (1999) A 76 (Abstract P 165)
19. Kretschmer V, Schikor B, Söhngen D, Dietrich G: In vitro bleeding test - A simple method for the detection of aspirin effects on platelet function. Thromb Res 56 (1989) 593-602
20. Kretschmer V: Clinical implications of the in vitro bleeding test - A review. Infusionsther Transfusionsmed 24 (1997) 428-434
21. Kretschmer V: Perioperatives Blutungsrisiko bei Einnahme von ASS bei urologischen Operationen. Urologe 6 (1998) 675-676
22. Lawrence C, Sakuntabhai A, Tiling-Grosse S: Effect of aspirin and nonsteroidal antiinflammatory drug therapy on bleeding complications in dermatologic surgical patients. J Am Acad Dermatol 31 (1994) 988-992
23. Lethagen S, Tennvall G R: Self-treatment with desmopressin intranasal spray in patients with bleeding disorders: Effect on bleeding symptoms and socioeconomic factors. Ann Hematol 66 (1993) 257-260
24. Lethagen S: Desmopressin - a hemostatic drug: state-of-the-art review. Eur J Anesthesiol 14 (Suppl 14) (1997) 1-9
25. Mannucci P M, Alieri D, Faioni E: Vasopressin analogues -Their role in disorders of hemostasis. Ann NY Acad Sci 509 (1987) 71-81
26. Mannucci P M, Carsson S, Harris A S: Desmopressin, surgery and thrombosis. Thromb Hemost 71 (1994) 154-155
27. Mannucci P M, Lusher J M: Desmopressin and thrombosis. Lancet 2 (1989) 675-676
28. Ozen S, Saatci U, Bakkaloglu A, Ozdemir S, Ozdemir O, Besbas N: Low-dose intranasal Desmopressin (DDAVP) for uremic bleeding. Nephron 75 (1997) 119-120 (Letter).
29. Peterson P, Hayes T E, Arkin C F, Bovill E G, Fairweather R B, Rock W A, Triplett D A, Brandt J T: The preoperative bleeding time test lacks clinical benefit. Arch Surg 133 (1998) 134-139
30. Saari A, Klvilaakso E, Inberg M, Pääkkönen M, Lahtinen J, Höckerstedt K, Schröder T: Comparison of somastotatin und vasopressin in bleeding esophageal varices. Am J Gastroenterology 85 (1990) 804-807
31. Schulman S, Johnsson H, Egberg N, Blombäck M: DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thromb Res 45 (1987) 165-174
32. Thommen D, Sulzer I, Buhrfeind E, Naef R, Furlan M, Lümmle B: Messung der Blutungszeit und Untersuchung der Thrombozytenaggregation. Schweiz med Wschr 118 (1988) 1559-1567
33. Ulshöfer B, Dorst V, Kretschmer V, Köhl H, Riedmüller H: Hemostaseological management of urological operations in patients taking aspirin using the Thrombostat 4000. Semin Thromb Hemost 21 (suppl 2) (1995) 52-58
34. Warrier I, Lusher J M: Congenital thrombocytopenias. Current Opinion in Hematology 2 (1995) 395-401
35. Weigert A L, Schafer A I: Uremic bleeding: Pathogenesis and therapy. Am J Med Sci 316 (1998) 94-104
36. Weippert-Kretschmer M, Möller A, Kretschmer V: Platelet Function Analyzer (PFA-100) for screening of von Willebrand's disease (vWD). Ann Hematol 74 (suppl 2) (1997) A147
37. Weippert-Kretschmer M, Witte M, Budde U, Vigh T, Kretschmer V, Scharrer I: The Thrombostat 4000-A sensitive screening test for the von Willebrand's disease. Semin Thromb Hemost 21 (suppl 2) (1995) 44-51
38. Zwaginga J J, Ijsseldijk J W, Beeser-Visser N, de Groot P G, Vos J, Sixma J J: High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. Blood 75 (1990) 1498-1508.